64 related articles for article (PubMed ID: 21034743)
1. MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism.
Polański R; Warburton HE; Ray-Sinha A; Devling T; Pakula H; Rubbi CP; Vlatković N; Boyd MT
FEBS Lett; 2010 Nov; 584(22):4695-702. PubMed ID: 21034743
[TBL] [Abstract][Full Text] [Related]
2. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
3. MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.
Polanski R; Maguire M; Nield PC; Jenkins RE; Park BK; Krawczynska K; Devling T; Ray-Sinha A; Rubbi CP; Vlatkovic N; Boyd MT
Carcinogenesis; 2011 Aug; 32(8):1133-42. PubMed ID: 21504894
[TBL] [Abstract][Full Text] [Related]
4. Mdm2-mediated ubiquitylation: p53 and beyond.
Marine JC; Lozano G
Cell Death Differ; 2010 Jan; 17(1):93-102. PubMed ID: 19498444
[TBL] [Abstract][Full Text] [Related]
5. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
6. P53 mRNA controls p53 activity by managing Mdm2 functions.
Candeias MM; Malbert-Colas L; Powell DJ; Daskalogianni C; Maslon MM; Naski N; Bourougaa K; Calvo F; Fåhraeus R
Nat Cell Biol; 2008 Sep; 10(9):1098-105. PubMed ID: 19160491
[TBL] [Abstract][Full Text] [Related]
7. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.
Linke K; Mace PD; Smith CA; Vaux DL; Silke J; Day CL
Cell Death Differ; 2008 May; 15(5):841-8. PubMed ID: 18219319
[TBL] [Abstract][Full Text] [Related]
8. Convergent solid-phase and solution approaches in the synthesis of the cysteine-rich Mdm2 RING finger domain.
Vasileiou Z; Barlos K; Gatos D
J Pept Sci; 2009 Dec; 15(12):824-31. PubMed ID: 19824037
[TBL] [Abstract][Full Text] [Related]
9. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?
Noon AP; Vlatković N; Polański R; Maguire M; Shawki H; Parsons K; Boyd MT
Cancer; 2010 Feb; 116(4):780-90. PubMed ID: 20052733
[TBL] [Abstract][Full Text] [Related]
10. E2F1 inhibits MDM2 expression in a p53-dependent manner.
Tian X; Chen Y; Hu W; Wu M
Cell Signal; 2011 Jan; 23(1):193-200. PubMed ID: 20837136
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53.
Arena G; Cissé MY; Pyrdziak S; Chatre L; Riscal R; Fuentes M; Arnold JJ; Kastner M; Gayte L; Bertrand-Gaday C; Nay K; Angebault-Prouteau C; Murray K; Chabi B; Koechlin-Ramonatxo C; Orsetti B; Vincent C; Casas F; Marine JC; Etienne-Manneville S; Bernex F; Lombès A; Cameron CE; Dubouchaud H; Ricchetti M; Linares LK; Le Cam L
Mol Cell; 2018 Feb; 69(4):594-609.e8. PubMed ID: 29452639
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 increases cellular invasiveness by binding to and stabilizing the Slug mRNA.
Jung CH; Kim J; Park JK; Hwang SG; Moon SK; Kim WJ; Um HD
Cancer Lett; 2013 Jul; 335(2):270-7. PubMed ID: 23438693
[TBL] [Abstract][Full Text] [Related]
14. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function.
Chen D; Zhang Z; Li M; Wang W; Li Y; Rayburn ER; Hill DL; Wang H; Zhang R
Oncogene; 2007 Aug; 26(35):5029-37. PubMed ID: 17310983
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2.
Min SH; Kim DM; Heo YS; Kim HM; Kim IC; Yoo OJ
Life Sci; 2010 Jan; 86(1-2):66-72. PubMed ID: 19945467
[TBL] [Abstract][Full Text] [Related]
16. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
[TBL] [Abstract][Full Text] [Related]
17. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation.
Yang JY; Zong CS; Xia W; Wei Y; Ali-Seyed M; Li Z; Broglio K; Berry DA; Hung MC
Mol Cell Biol; 2006 Oct; 26(19):7269-82. PubMed ID: 16980628
[TBL] [Abstract][Full Text] [Related]
18. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53.
Carter S; Bischof O; Dejean A; Vousden KH
Nat Cell Biol; 2007 Apr; 9(4):428-35. PubMed ID: 17369817
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
[TBL] [Abstract][Full Text] [Related]
20. p53 regulation and function in renal cell carcinoma.
Warburton HE; Brady M; Vlatković N; Linehan WM; Parsons K; Boyd MT
Cancer Res; 2005 Aug; 65(15):6498-503. PubMed ID: 16061625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
